271 related articles for article (PubMed ID: 19893491)
1. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin.
Wickström SA; Masoumi KC; Khochbin S; Fässler R; Massoumi R
EMBO J; 2010 Jan; 29(1):131-44. PubMed ID: 19893491
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of cylindromatosis gene, CYLD, confers a growth advantage on malignant melanoma cells while negatively regulating their migration activity.
Ishikawa Y; Tsunoda K; Shibazaki M; Takahashi K; Akasaka T; Masuda T; Maesawa C
Int J Oncol; 2012 Jul; 41(1):53-60. PubMed ID: 22469839
[TBL] [Abstract][Full Text] [Related]
3. CYLD mediates ciliogenesis in multiple organs by deubiquitinating Cep70 and inactivating HDAC6.
Yang Y; Ran J; Liu M; Li D; Li Y; Shi X; Meng D; Pan J; Ou G; Aneja R; Sun SC; Zhou J
Cell Res; 2014 Nov; 24(11):1342-53. PubMed ID: 25342559
[TBL] [Abstract][Full Text] [Related]
4. Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl.
Tauriello DV; Haegebarth A; Kuper I; Edelmann MJ; Henraat M; Canninga-van Dijk MR; Kessler BM; Clevers H; Maurice MM
Mol Cell; 2010 Mar; 37(5):607-19. PubMed ID: 20227366
[TBL] [Abstract][Full Text] [Related]
5. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling.
Massoumi R; Chmielarska K; Hennecke K; Pfeifer A; Fässler R
Cell; 2006 May; 125(4):665-77. PubMed ID: 16713561
[TBL] [Abstract][Full Text] [Related]
6. CENPV Is a CYLD-Interacting Molecule Regulating Ciliary Acetylated α-Tubulin.
Chiticariu E; Regamey A; Huber M; Hohl D
J Invest Dermatol; 2020 Jan; 140(1):66-74.e4. PubMed ID: 31260673
[TBL] [Abstract][Full Text] [Related]
7. The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration.
Gao J; Huo L; Sun X; Liu M; Li D; Dong JT; Zhou J
J Biol Chem; 2008 Apr; 283(14):8802-9. PubMed ID: 18222923
[TBL] [Abstract][Full Text] [Related]
8. Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity.
Almeida S; Maillard C; Itin P; Hohl D; Huber M
J Invest Dermatol; 2008 Mar; 128(3):587-93. PubMed ID: 17851586
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase 6 (HDAC6) is an independent deacetylase for alpha-tubulin.
Zhao Z; Xu H; Gong W
Protein Pept Lett; 2010 May; 17(5):555-8. PubMed ID: 19961433
[TBL] [Abstract][Full Text] [Related]
10. CYLD regulates keratinocyte differentiation and skin cancer progression in humans.
Alameda JP; Fernández-Aceñero MJ; Moreno-Maldonado R; Navarro M; Quintana R; Page A; Ramírez A; Bravo A; Casanova ML
Cell Death Dis; 2011 Sep; 2(9):e208. PubMed ID: 21900959
[TBL] [Abstract][Full Text] [Related]
11. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.
Haggarty SJ; Koeller KM; Wong JC; Grozinger CM; Schreiber SL
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4389-94. PubMed ID: 12677000
[TBL] [Abstract][Full Text] [Related]
12. CYLD Inhibits the Development of Skin Squamous Cell Tumors in Immunocompetent Mice.
Alameda JP; García-García VA; López S; Hernando A; Page A; Navarro M; Moreno-Maldonado R; Paramio JM; Ramírez Á; García-Fernández RA; Casanova ML
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201751
[TBL] [Abstract][Full Text] [Related]
13. HDAC6 is a microtubule-associated deacetylase.
Hubbert C; Guardiola A; Shao R; Kawaguchi Y; Ito A; Nixon A; Yoshida M; Wang XF; Yao TP
Nature; 2002 May; 417(6887):455-8. PubMed ID: 12024216
[TBL] [Abstract][Full Text] [Related]
14. Modulation of histone deacetylase 6 (HDAC6) nuclear import and tubulin deacetylase activity through acetylation.
Liu Y; Peng L; Seto E; Huang S; Qiu Y
J Biol Chem; 2012 Aug; 287(34):29168-74. PubMed ID: 22778253
[TBL] [Abstract][Full Text] [Related]
15. GLI1-dependent transcriptional repression of CYLD in basal cell carcinoma.
Kuphal S; Shaw-Hallgren G; Eberl M; Karrer S; Aberger F; Bosserhoff AK; Massoumi R
Oncogene; 2011 Nov; 30(44):4523-30. PubMed ID: 21577203
[TBL] [Abstract][Full Text] [Related]
16. Transition from cylindroma to spiradenoma in CYLD-defective tumours is associated with reduced DKK2 expression.
Rajan N; Burn J; Langtry J; Sieber-Blum M; Lord CJ; Ashworth A
J Pathol; 2011 Jul; 224(3):309-21. PubMed ID: 21598248
[TBL] [Abstract][Full Text] [Related]
17. Loss of CYLD might be associated with development of salivary gland tumors.
Fukuda M; Hiroi M; Suzuki S; Ohmori Y; Sakashita H
Oncol Rep; 2008 Jun; 19(6):1421-7. PubMed ID: 18497946
[TBL] [Abstract][Full Text] [Related]
18. Functional interplay between cylindromatosis and histone deacetylase 6 in ciliary homeostasis revealed by phenotypic analysis of double knockout mice.
Ran J; Yu F; Qin J; Zhang Y; Yang Y; Li D; Zhou J; Liu M
Oncotarget; 2016 May; 7(19):27527-37. PubMed ID: 27028867
[TBL] [Abstract][Full Text] [Related]
19. MeCP2 deficiency is associated with reduced levels of tubulin acetylation and can be restored using HDAC6 inhibitors.
Gold WA; Lacina TA; Cantrill LC; Christodoulou J
J Mol Med (Berl); 2015 Jan; 93(1):63-72. PubMed ID: 25209898
[TBL] [Abstract][Full Text] [Related]
20. Expression of CYLD, NF-kappaB and NF-kappaB-related factors in salivary gland tumors.
Fukuda M; Fukuda F; Horiuchi Y; Oku Y; Suzuki S; Kusama K; Sakashita H
In Vivo; 2006; 20(4):467-72. PubMed ID: 16900776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
